Insulet Corporation (PODD)

205,75 +1,81 (+0,89%) Alla chiusura: 04:00PM EDT

Insulet Corporation

100 Nagog Park
Acton, MA 01720
United States
978 600 7000
https://www.insulet.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 3.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. James R. Hollingshead Ph.D.	President, CEO & Director	2,88M	N/D	1963
Ms. Lauren Budden	Group VP, Chief Accounting Officer & Controller	794,05k	N/D	1975
Mr. Mark Field	Senior VP & CTO	954,14k	N/D	1971
Mr. John Wodick Kapples	Senior VP & General Counsel	1,02M	N/D	1960
Mr. Eric Benjamin	Executive VP, Chief Product & Customer Experience Officer	1,14M	N/D	1983
Ms. Ana Maria Chadwick	Executive VP, CFO & Treasurer	N/D	N/D	1972
Mr. Prem Singh	Senior Vice President of Global Operations	N/D	N/D	1977
Ms. Deborah R. Gordon CPA	Vice President of Investor Relations	N/D	N/D	1971
Ms. Laetitia Cousin	Senior VP of Regulatory Affairs, Quality Assurance & Compliance	N/D	N/D	1976
Angela Geryak Wiczek	Senior Director of Corporate Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Insulet Corporation al 1 giugno 2024 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 10; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.